Drug Type Interferons, Biosimilar |
Synonyms Peg IFN α-2b, PegiHep, Peginterferon alpha 2b biosimilar + [2] |
Target |
Action agonists, stimulants, inducers |
Mechanism IFNAR agonists(Interferon alpha/beta receptor agonists), Immunostimulants, Innate antiviral immune response inducers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (01 Jan 2014), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Condylomata Acuminata | Japan | 01 Jan 2014 | |
Hepatitis B | Japan | 01 Jan 2014 | |
Hepatitis C | Japan | 01 Jan 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 2 | Mexico | 11 Aug 2020 |
Not Applicable | Myeloproliferative Disorders JAK2V617F mutation | CALR mutation | MPL mutation | 68 | PEG IFNα-2b 180μg once a week | heudeaoxnf(jrfdyzgrds) = rremgqxvvc nvagtapzkk (avjjdgomlc ) View more | Positive | 14 May 2024 | |
Not Applicable | 81 | mqtyzvdlav(fuhrtocjyh) = wsqlyssftc uncduvjftl (oysuthpjac ) | Positive | 14 May 2024 | |||
Not Applicable | 21 | palbhakskz(dyaklnowkc) = All adverse reactions were controllable by temporary suspension of treatment. Serious complications and treatment related deaths were not observed. kdkihfgonv (wpntpkzaks ) | Positive | 26 Feb 2018 | |||
Phase 1/2 | 17 | iskhvwohff(cpszekngvb) = aqmunhbmeq dcwtwhxwpz (yqzxwobzyg ) View more | - | 15 Apr 2012 | |||
Not Applicable | 121 | dvvsngxwca(dnyisofjfe) = tguiestkvx tutqevlfho (qgkmzhpjbd ) | - | 01 Jan 2003 |